Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2007-05-25
2008-11-18
Ouspenski, Ilia (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C424S133100, C424S135100, C424S141100, C424S144100, C424S154100, C530S387100, C530S387300, C530S388100, C530S388220, C530S388750
Reexamination Certificate
active
07452536
ABSTRACT:
Methods and compositions for regulating immunity are disclosed. For enhancing an immune response, agents that inhibit OX-2 are administered. Such methods are useful in treating cancer. For suppressing an immune response, an OX-2 protein or a nucleic acid encoding an OX-2 protein is administered. Such methods are useful in preventing graft rejection, fetal loss, autoimmune disease, allergies and in inducing tumor cell growth.
REFERENCES:
patent: 5434131 (1995-07-01), Linsley et al.
patent: 5916560 (1999-06-01), Linsley et al.
patent: 6338851 (2002-01-01), Gorczynski
patent: 6955811 (2005-10-01), Gorczynski et al.
patent: 7238352 (2007-07-01), Gorczynski et al.
patent: WO 97/21450 (1997-06-01), None
patent: WO 99/24565 (1999-05-01), None
Huang Z., Pharmacology and Therapeutics, 2000, 86: 201-215.
Auchincloss, H., Jr. 1995 Transplantation Immunology, 211-218.
Barclay, 1981, Immunology, 44, pp. 727-736.
Barclay et al., 1982, European Journal Biochem, 129, pp. 447-458.
Borriello, F. et al., 1998, Mammalian Genome, February, 9(2), pp. 114-118.
Borriello, F. et al., 1997, J. Immunology, 158, pp. 4549-4554.
Chen, Z. et al., Database Medline, 1997, Biochimica et Biophysica Acta, Nov. 28, 1362(1), pp. 6-10.
Clark, D.A. et al. Labile CD200 tolerance signal important in transfusion-related immunomodulation (TRIM) prevention of recurrent miscarriages. Amer. J. Reprod. Immunol. 45; 361.
Gorczynski, R.M., et al., 1998, Transplantation, Apr. 27, 65(8), pp. 1106-1114.
Gorczynski, R.M., et al., 1999, J. Immunol., 163:1654-1660.
Preston, S. et al., 1997, European Journal of Immunology, vol. 27, No. 8, pp. 1911-1918.
Ni, J. et al., An immunoadhesin incorporating the molecule OX-2 is a potent immunosuppressant which prolongs allograft survival, FASEB Journal, vol. 13, No. 5, p. A983 (1999).
Ragheb, R. et al., Preparation and functional properties of monoclonal antibodies to human, mouse and rat OX-2, Immunology Letters, vol. 68, No. 2-3, p. 311-315 (1999).
Jain, Nature Medicine, 1998; 4(6):655-657.
Kim et al., Cancer Res., 2001; 61:2031-2037.
Kjaergaard et al., Cancer Res., 2000; 60:5514-5521.
Boon, Adv. Cancer Res., 1992: 58:177-210.
Huang, Pharmacol. Therapeutics, 2000; 86:201-215.
Pardoll, Clin. Immunol., 2000; 95(1): S44-S62.
Clark, M.J. et al. “MRC OX-2 antigen: a lymphoid
euronal membrane glycoprotein with a structure like a single immunoglobulin light chain”, The EMBO Journal, vol. 4, No. 1, p. 113-118 (1985).
Gorczynski, R.M. et al. “Evidence of a role for CD200 in regulation of immune rejection of leukaemic tumour cells in C57BL/6 mice”, Clin. Exp. Immunol. 126:220-229 (2001).
Mjaaland and Fossum “Modulation of immune responses with monoclonal antibodies I. Effects on regional lymph node morphology and on anti-hapten responses to haptenized monoclonal antibodies”, Eur. J. Immunol. 20:1457-1461 (1990).
Clark David A.
Gorczynski Reginald M.
Bereskin & Parr
Gravelle Micheline
Ouspenski Ilia
Trillium Therapeutics Inc.
LandOfFree
Methods of treating cancer by administering antibodies to CD200 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treating cancer by administering antibodies to CD200, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating cancer by administering antibodies to CD200 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4050647